Editorial: acid suppression with potassium‐competitive acid blockers dismissing genotype concerns-Reference-Cited by-同舟云学术

Editorial: acid suppression with potassium‐competitive acid blockers dismissing genotype concerns

Published:2020-12-17 Issue:1 Volume:53 Page:187-188
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Scarpignato Carmelo¹²³^ORCID,Hunt Richard H.⁴

Affiliation:

1. Faculty of Health Sciences LUdeS Lugano Campus Lugano Switzerland

2. United Campus of Malta Msida Malta

3. Faculty of Medicine Chinese University of Hong Kong Shatin Hong Kong

4. Division of Gastroenterology and Farncombe Family Digestive Health Research Institute Department of Medicine McMaster University Hamilton ON Canada

Abstract

LINKED CONTENT This article is linked to Hwang et al and Hwang & Lee papers. To view these articles, visit https://doi.org/10.1111/apt.16131 and https://doi.org/10.1111/apt.16158

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16139

Reference10 articles.

1. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression

2. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor

3. The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis

4. FDA.Table of Pharmacogenetic Associations.https://www.fda.gov/medical‐devices/precision‐medicine/table‐pharmacogenetic‐associations2020.

5. Potent Acid Suppression with PPIs and P-CABs: What’s New?

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease;Expert Opinion on Drug Metabolism & Toxicology;2024-08-27

2. Advances in Drug Treatment of Refractory Gastroesophageal Reflux Disease;Advances in Clinical Medicine;2024

3. Editorial: pharmacokinetic and pharmacodynamic model for vonoprazan—a step forward to precision medicine;Alimentary Pharmacology & Therapeutics;2023-06-12

4. Helicobacter pylori culture: from bench to bedside;Annals of Gastroenterology;2022

5. Refractory Gastroesophageal Reflux Disease: A Management Update;Frontiers in Medicine;2021-11-01